Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3862781

CCC1CNCCO1.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18528199 1.00
SCHEMBL3168 0.98
SCHEMBL12524834 0.98
Fluoride SCHEMBL7750151 0.98
SCHEMBL7097741 0.98
SCHEMBL322796 0.98
Bromide SCHEMBL1608720 0.95
Ammonia Solution, Strong SCHEMBL331668 0.95
Water SCHEMBL7481154 0.95
SCHEMBL3663947 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113277954-B Amino acid metal chelate micro-nano powder and preparation method thereof 英德市匠心新材料股份有限公司 2023-04-28 CN claimed
CN-105228606-A Composition of alpha-2 adrenergic receptor and sigma receptor ligand ESTEVE LABOR DR 2016-01-06 CN claimed
CN-103052388-A Use of sigma ligands in opioid-induced hyperalgesia ESTEVE LABOR DR 2013-04-17 CN claimed
CN-119663385-A Leveling agent and preparation method thereof, copper electroplating solution and copper electroplating method 广东东硕科技有限公司 2025-03-21 CN disclosed
EP-4304554-A1 DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES Aquestive Therapeutics, Inc. (US) 2024-01-17 EP disclosed
EP-3965721-A1 TOPICAL COMPOSITIONS DSM IP Assets B.V. (NL) 2022-03-16 EP disclosed
EP-3965722-A1 TOPICAL COMPOSITIONS DSM IP Assets B.V. (NL) 2022-03-16 EP disclosed
WO-2021224203-A1 THE USE OF HYPERBRANCHED COPOLYMERS FOR BALANCING MICROBIAL GROWTH DSM IP ASSETS B.V. (NL) 2021-11-11 WO disclosed
WO-2020229262-A1 TOPICAL COMPOSITIONS DSM IP ASSETS B.V. (NL) 2020-11-19 WO disclosed
WO-2020229259-A1 TOPICAL COMPOSITIONS DSM IP ASSETS B.V. (NL) 2020-11-19 WO disclosed
EP-3723714-A1 PROPANEDIOL MONOACETATE MONONITRATE DSM IP Assets B.V. (NL) 2020-10-21 EP disclosed
EP-2892339-A1 NOVEL COMPOSITIONS COMPRISING P-HYDROXYBENZYLAMINE DSM IP Assets B.V. (NL) 2015-07-15 EP disclosed
WO-2014032954-A1 NOVEL COMPOSITIONS COMPRISING P-HYDROXYBENZYLAMINE DSM IP ASSETS B.V. (NL) 2014-03-06 WO disclosed
CN-102066333-A 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors ESTEVE LABOR DR 2011-05-18 CN disclosed
EP-1509220-A4 A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4- 2-METHYL-3(3-METHYL-2-BUTENYL)-2-OXIRANYL -1-OXASPIRO 2,5 OCTAN-6-ONE MYCOPLUS CO LTD (KR) 2009-04-01 EP disclosed
EP-1509220-A1 A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4- 2-METHYL-3(3-METHYL-2-BUTENYL)-2-OXIRANYL]-1-OXASPIRO 2,5]OCTAN-6-ONE Mycoplus Co., Ltd. (KR) 2005-03-02 EP disclosed
CN-1466572-A Pyrrole derivatives ס����ҩ��ʽ���� 2004-01-07 CN disclosed
WO-2003094908-A1 A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4-[2-METHYL-3(3-METHYL-2-BUTENYL)-2-OXIRANYL]-1-OXASPIRO[2,5]OCTAN-6-ONE MYCOPLUS CO., LTD. (KR) 2003-11-20 WO disclosed
EP-1360146-A1 PROCESS FOR THE PREPARATION OF AQUEOUS SUSPENSIONS OF ANIONIC COLLOIDAL SILICA HAVING A NEUTRAL PH AND APPLICATIONS THEREOF Clariant International Ltd. (CH) 2003-11-12 EP disclosed
WO-2002055434-A1 PROCESS FOR THE PREPARATION OF AQUEOUS SUSPENSIONS OF ANIONIC COLLOIDAL SILICA HAVING A NEUTRAL PH AND APPLICATIONS THEREOF CLARIANT FINANCE (BVI) LIMITED (VG) 2002-07-18 WO disclosed